BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 29, 2003
View Archived Issues
Cholinergic ligands claimed by NeuroSearch patent for CNS disorders
Read More
Series of substituted phenylacetamides described in Roche patent
Read More
Esters of camptothecins with enhanced anticancer activity described in recent patent
Read More
Glaxo patent describes a series of dopamine receptor modulators with antipsychotic properties
Read More
Semisynthetic erythromycins prepared by Enanta
Read More
NicOx designs treatments for hepatic and portal venous circulation disorders
Read More
NeuroSearch, GlaxoSmithKline collaborate on CNS drug development
Read More
PARP inhibitors prevent hypoglycemic shock-induced neuronal death
Read More
Phase II results support efficacy of NovoSeven in trauma
Read More
Eiken will market SARS detection kit in Japan
Read More
Exelixis files IND for phase III trial of XL-119
Read More
Genmab files to conduct phase I/II HuMax-CD20 trial for NHL
Read More
Target enrollment reached in ASCENT trial of DN-101
Read More
Zenergen may reduce fat, enhance weight loss
Read More
NXC-4720 reduces E. coli contamination in meat
Read More
New Zealand approves Thalidomide for multiple myeloma
Read More
510(K) clearance for RedLine Alert B. anthracis test kit
Read More
The Medicines Company acquires cangrelor from AstraZeneca
Read More
European registration dossier for Daxas set for submission in February 2004
Read More
Menactra BLA submitted
Read More
Lundbeck advances new compounds into phase I
Read More
MLN-3897 enters phase I
Read More
Dosing starts in phase I study of transdermal PTH
Read More
Elan to sell European sales and marketing business to Medeus
Read More
ALX-2732 identified as a novel, highly potent and selective human 5-HT1D receptor agonist
Read More
Clinical effects of tipifarnib in hematological malignancies
Read More